- Previous Close
0.315 - Open
0.315 - Bid 0.325 x --
- Ask 0.340 x --
- Day's Range
0.300 - 0.345 - 52 Week Range
0.245 - 0.600 - Volume
8,898,000 - Avg. Volume
2,786,440 - Market Cap (intraday)
204M - Beta (5Y Monthly) 0.39
- PE Ratio (TTM)
17.00 - EPS (TTM)
0.020 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date May 25, 2022
- 1y Target Est
--
Modern Chinese Medicine Group Co., Ltd., an investment holding company, engages in the production and sale of proprietary Chinese medicines for elderlies and middle aged in the People's Republic of China. The company offers vigour and vitality supplement, circulation enhancement, kidney invigoration, menstrual discomfort relief, huoxiang zheng qi, liver-dispersing and stomach regulating, and fever- removing and detoxification pills; cardiotonic enhancement and heart wellness capsules; and liver detox tablets. It offers its products as therapeutics for the qi-deficiency and blood-statis, cardio-cerebrovascular, digestive and gastrointestinal, gynecological, and respiratory system conditions. It also provides business support, technical, and consulting services. The company was founded in 1986 and is headquartered in Chengde, China. Modern Chinese Medicine Group Co., Ltd. operates as a subsidiary of Modern Biotechnology Group Holdings Co., Ltd.
www.cdysjdyy.com190
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 1643.HK
View MorePerformance Overview: 1643.HK
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1643.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1643.HK
View MoreValuation Measures
Market Cap
189.00M
Enterprise Value
-54.98M
Trailing P/E
18.41
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.83
Price/Book (mrq)
0.37
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
4.52%
Return on Assets (ttm)
2.79%
Return on Equity (ttm)
2.02%
Revenue (ttm)
214.07M
Net Income Avi to Common (ttm)
9.67M
Diluted EPS (ttm)
0.020
Balance Sheet and Cash Flow
Total Cash (mrq)
229.67M
Total Debt/Equity (mrq)
0.03%
Levered Free Cash Flow (ttm)
--